Epstein-Barr virus peptide-MHC class I complex (EBV pMHC-I)

The Epstein-Barr virus (EBV) peptide-MHC class I complex is a critical therapeutic target in the treatment of EBV-associated malignancies and post-transplant lymphoproliferative disorders (PTLD) (NIH, 2024; Frontiers in Immunology, 2024). This target consists of viral peptides derived from latent or lytic EBV proteins—such as EBNA1, EBNA3, and LMP2—which are processed and presented on the cell surface by the host's major histocompatibility complex (MHC) class I molecules (NIH, 2019; Frontiers in Immunology, 2021). These complexes are specifically recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T lymphocytes (CTLs), which then eliminate the infected or malignant cells through the release of perforins and granzymes (PatSnap, 2024; VJHemOnc, 2024). Therapeutic interventions targeting these complexes include adoptive cell therapies like Tabelecleucel (Ebvallo), the first approved allogeneic EBV-specific T-cell therapy, as well as experimental TCR-engineered T cells (NIH, 2024; Blood, 2022). A significant challenge in targeting this complex is the virus's ability to evade immune detection by downregulating MHC class I expression or inhibiting antigen processing (NIH, 2019; NIH, 2010). Additionally, the high polymorphism of HLA alleles requires precise matching between the therapeutic T cells and the patient's MHC profile for effective recognition (VJHemOnc, 2024; ImmunoSpot, 2024). Monitoring EBV DNA load and HLA typing are essential biomarkers for patient selection and efficacy assessment in these therapies (Frontiers in Immunology, 2024; NIH, 2024).

Other names

Epstein-Barr virus peptide antigens presented by MHC class IEBV peptide-HLA class I complexEBV-specific T-cell targetHLA-restricted EBV antigensEBV pMHC

Adoptive T-cell therapy where T-cell receptors (TCRs) recognize specific EBV peptides presented by MHC class I molecules on the surface of infected or malignant cells, triggering cytotoxic activity and apoptosis of the target cell.